The Promise of Merck's Pembrolizumab in PD-L1-expressing NSCLC

Pembrolizumab was safe and effective in patients with locally advanced or metastatic non–small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.
Published Online: June 11, 2014

Edward B. Garon, MD, assistant clinical professor and director of the thoracic oncology program at the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues sought to evaluate pembrolizumab (Merck) — previously known as lambrolizumab and MK-3475 — among patients with previously treated advanced NSCLC.

“We presented the initial data from lung cancer patients at the World Conference on Lung Cancer in Sydney last fall,” Garon told HemOnc Today. “The question at that time was whether the impressive efficacy and tolerable safety profile could be confirmed in a larger population. We have now demonstrated similar results in over 200 additional patients.”

The analysis included 217 patients who were tested for PD-L1 expression using immunohistochemistry (IHC).

Read the report here:

Source: Healio

Recommended Articles
New research studies show that anti-inflammatory agents can improve survival as well as quality of life in cancer patients.
Physicians at the Brigham and Women’s Hospital have published results from a proof-of-concept study that used mass spectrometry in almost real-time to detect and delineate pituitary tumors from normal tissue.
Genevieve Kumapley, PharmD, BCOP, reflects on the significant out-of-pocket costs associated with oral oncolytics and suggests how a change in benefit design can help patients afford the treatments they need.
During this segment, Genevieve Kumapley, PharmD, BCOP, discusses the significance of introducing a self-care plan to patients who are undergoing cancer treatment.
Two inexpensive generic drugs have been shown to reduce breast cancer deaths in postmenopausal women, according to studies published in The Lancet.